1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,000 | 8,000 | 22:58 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ABL Diagnostics Presents Its Financial Roadmap and Growth Outlook for 2026 | 205 | Business Wire | Full-year 2026 revenue target set at €12.27 million, delivering an exceptional +76.5% growth compared to 2025 Historic shift in scale driven by the full-year impact of growth drivers (FTD... ► Artikel lesen | |
| 19.05. | Allinvest Reiterates Its "BUY" Rating on ABL Diagnostics and Maintains a €8.4 Target Price (Representing a 2.2X Multiple) | 277 | Business Wire | Massive upside potential of +123.4% compared to the closing price of €3.76 (as of May 18, 2026). Historic 2025 results: Revenue up +30.4% to €6.95m, net profit surging to €0.98m (+246%)... ► Artikel lesen | |
| ABL DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 18.05. | ABL Diagnostics SA: ABL Diagnostics Proposes a Significant Increase in Its Dividend for FY2025 | 247 | Business Wire | Proposed dividend of €0.11 per share, up +120%, reflecting the Company's improved financial performance and solid financial position
Regulatory News:
ABL Diagnostics (Euronext Paris FR001400AHX6)... ► Artikel lesen | |
| 11.05. | ABL Diagnostics Reports Historic 2025 Annual Results: Net Income Explosion (+246%), Strong Operating Profitability and Global Acceleration | 278 | Business Wire | Strong revenue growth of +30.4% to €6.95m Positive operating income of €290k, exceeding analyst forecasts Net income soaring to nearly €1m (€987k) International business acceleration:... ► Artikel lesen | |
| 08.05. | ABL Diagnostics: Availability of the 2025 Annual Financial Report | 357 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF).
The... ► Artikel lesen | |
| 17.03. | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 336 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 19.02. | ABL Diagnostics S.A.: ABL Diagnostics Update Regarding Non-Binding Letter of Intent | 337 | Business Wire | Regulatory News:
ABL Diagnostics S.A. (Euronext: ABLD ISIN: FR001400AHX6) informs the market that the non-binding Letter of Intent entered into between ProPhase Labs, Inc. and Advanced Biological... ► Artikel lesen | |
| 13.02. | ABL Diagnostics SA: ABL SA Executes the First Purchase Notice of ABL Diagnostics Shares With Alumni Capital | 571 | Business Wire | Regulatory News:
ISIN: FR001400AHX6 Euronext Paris
ABL Diagnostics SA ("the Company") (Paris:ABLD) informs the public that its principal shareholder, Advanced Biological Laboratories SA (ABL... ► Artikel lesen | |
| 03.02. | ABL Diagnostics: Sale of a New Block of Shares by Its Main Shareholder ABL | 400 | Business Wire | Regulatory News:
ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the... ► Artikel lesen | |
| 19.12.25 | ABL Diagnostics Informs the Market of a Non-Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger | 463 | Business Wire | The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.'s control over ABL Diagnostics at... ► Artikel lesen | |
| 05.12.25 | ABL Diagnostics S.A.: Information on a Temporary Transfer of ABL Diagnostics Shares | 432 | Business Wire | Regulatory News:
ABL Diagnostics S.A. (ISIN: FR001400AHX6, ticker: ABLD, listed on Euronext Paris) informs its shareholders and the market that a temporary transfer of 128,026 shares of the company... ► Artikel lesen | |
| 14.11.25 | ABL Diagnostics Appoints Eurobio Scientific as Exclusive Distributor for Its VELA Product Line in a Targeted Segment of the French Market | 399 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio... ► Artikel lesen | |
| 22.10.25 | ABL Diagnostics SA: ABL Diagnostics - Announcement of a Second Agreement Between ABL SA and Alumni Capital | 335 | Business Wire | Regulatory News:
ISIN: FR001400AHX6 Euronext Paris
ABL Diagnostics SA (the "Company") (Paris:ABLD) informs the public that Advanced Biological Laboratories SA (ABL SA), its parent company, announced... ► Artikel lesen | |
| 16.10.25 | ABL Diagnostics SA: ABL Diagnostics: Switch to Continuous Trading on Euronext Paris as From November 3rd, 2025 | 412 | Business Wire | Regulatory News:
ABL Diagnostics (Euronext Paris: ABLD ISIN: FR001400AHX6) announces the switch from a fixing-based trading mode to continuous trading as from November 3rd, 2025, in accordance... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 34,040 | -0,64 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. a) der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung (EU)... ► Artikel lesen | |
| THERMO FISHER | 416,40 | -1,95 % | Laufende Fusionskontrollverfahren: Astorg Group S.à.r.l., Luxemburg; mittelbarer Erwerb alleiniger Kontrolle über den Mikrobiologie-Geschäftsbereich von Thermo Fisher Scientific Inc., Waltham/MA/USA (u.a. Oxoid Deutschland GmbH) | Datum der Anmeldung:22.05.2026Aktenzeichen:B3-68/26Unternehmen:Astorg Group S.à.r.l., Luxemburg; mittelbarer Erwerb alleiniger Kontrolle über den Mikrobiologie-Geschäftsbereich von Thermo Fisher Scientific... ► Artikel lesen | |
| STRATEC | 16,780 | -1,87 % | Stratec-Aktie: Hier zählt die Zukunft | Die Aktie von Stratec befindet sich weiterhin in einer schwierigen Marktphase. Seit dem Hoch im Oktober bei rund 30 € dominiert ein langfristiger Abwärtstrend, der lediglich von zwischenzeitlichen Erholungsbewegungen... ► Artikel lesen | |
| UNIDOC HEALTH | 0,062 | +3,32 % | UniDoc Health Corp.: UniDoc Reflects on Successes One Year After AMD Telemedicine Software Purchase | AMD Telemedicine software and related systems now fully integrated; UniDoc Connect used at more than 800 sites across 48 countries VANCOUVER, BC / ACCESS Newswire / May 21, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| DIASORIN | 67,22 | +0,12 % | Dividendenbekanntmachungen (18.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A2A SPA IT0001233417 - 0,104 EUR AIR LIQUIDE SA FR0000120073 - 3,7 EUR ALCOA CORPORATION CDIS AU0000339426 0,1 USD 0,086 EUR ALLISON... ► Artikel lesen | |
| BIOCARTIS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.01.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 21.01.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.01.2026ISIN NameBE0974281132 BIOCARTIS... ► Artikel lesen | |
| FRESENIUS | 36,450 | +2,82 % | dpa-AFX-Überblick: UNTERNEHMEN vom 26.05.2026 - 15.15 Uhr | Schwerwiegende Bedenken: BP trennt sich von Verwaltungsratschef - Kursrutsch LONDON - Der britische Ölkonzern BP setzt seinen Verwaltungsratschef Albert Manifold wegen Vorwürfen vor die Tür. Als... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 35,690 | -1,95 % | EQS-Adhoc: Fresenius Medical Care AG: Fresenius Medical Care AG beschließt Aktienrückkaufprogramm mit einem Gesamtvolumen von rund EUR 1 Milliarde in Tranchen | EQS-Ad-hoc: Fresenius Medical Care AG / Schlagwort(e): Kapitalmaßnahmen / Aktienrückkäufe
Fresenius Medical Care AG: Fresenius Medical Care AG beschließt Aktienrückkaufprogramm mit... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 59,34 | -1,07 % | Morgan Stanley raises BrightSpring Health price target on valuation | ||
| ALIGNMENT HEALTHCARE | 13,640 | +2,56 % | Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report | ||
| BLUEJAY DIAGNOSTICS | 4,310 | +101,40 % | Morning Market Movers: Bluejay Diagnostics, Decent Holding, Abits Group, Sunshine Biopharma See Big Swings | WASHINGTON (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 26,760 | -3,95 % | Procept Biorobotics wins expanded FDA IDE for Aquablation, completes study enrollment | ||
| PROGYNY | 25,115 | -4,14 % | Progyny, Inc.: New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System | ||
| GENEDX | 53,07 | +2,08 % | GeneDx (WGS) Fell Despite Continued Execution Improvement | ||
| BILLIONTOONE | 94,01 | -5,03 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen |
Das Unternehmen ABL DIAGNOSTICS SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,05 % bei einem Aktienkurs von 2,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABL DIAGNOSTICS SA finden Sie auf Wallstreet Online.